Stonegate Updates Coverage on Burcon Nutrascience: Commercial Momentum Builds, but 2H Ramp Remains Key

Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from technology validation to commercial execution. Burcon's first-quarter fiscal 2027 results, reported in August 2026, show significant progress: revenue increased 54% quarter-over-quarter and 273% year-over-year to $1.28 million. The number of active buying customers grew to 40 from 30+ previously, and repeat purchasing continues to build, providing better visibility into recurring demand.

However, the results were mixed. A $1.76 million inventory write-down masked a much narrower underlying gross loss, indicating that the core business is improving but still not profitable. The focus now shifts to whether the company can sustain this customer traction and achieve the substantial second-half revenue ramp required to reach its prior CY26 sales objective of $10 million. To do so, Burcon would need approximately $7.9 million in second-half sales, a significant challenge given the current run rate.

Capacity and funding are now the key execution levers. Burcon plans to expand its Galesburg production facility, which will be critical to meeting increased demand. The company also has a planned financing of up to $8.1 million to bridge liquidity and support the production ramp. These initiatives are essential for Burcon to move toward positive cash flow, a milestone that remains a key focus for investors.

Stonegate's update underscores that while Burcon is making strides in commercial adoption, the path to profitability is still steep. The company's ability to execute on its expansion plans and secure additional funding will be crucial in the coming quarters. For more details, the full announcement can be viewed at Stonegate's website.